Onsdag 4 December | 12:23:24 Europe / Stockholm

Kalender

Tid*
2022-01-26 - Bokslutskommuniké 2021
2021-07-14 - Kvartalsrapport 2021-Q2
2021-06-30 - Årsstämma
2021-05-27 - X-dag ordinarie utdelning NATTO 0.00 NOK
2021-02-17 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2
2020-06-22 - X-dag ordinarie utdelning NATTO 0.00 NOK
2020-06-19 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-19 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning NATTO 0.00 NOK
2019-05-29 - Årsstämma
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-13 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning NATTO 0.00 NOK
2018-05-30 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-24 - Extra Bolagsstämma 2017
2017-08-16 - Kvartalsrapport 2017-Q2
2017-05-16 - X-dag ordinarie utdelning NATTO 0.00 NOK
2017-05-15 - Årsstämma
2017-05-15 - Kapitalmarknadsdag 2017
2017-05-15 - Kvartalsrapport 2017-Q1
2017-02-08 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-20 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2014-11-26 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-05-27 - Kvartalsrapport 2014-Q1
2014-02-17 - Bokslutskommuniké 2013
2013-11-26 - Kvartalsrapport 2013-Q3
2013-08-27 - Kvartalsrapport 2013-Q2
2013-05-22 - Kvartalsrapport 2013-Q1
2013-02-28 - Bokslutskommuniké 2012
2012-11-15 - Kvartalsrapport 2012-Q3
2012-08-21 - Kvartalsrapport 2012-Q2
2012-05-16 - Kvartalsrapport 2012-Q1
2012-02-28 - Bokslutskommuniké 2011
2012-02-13 - Extra Bolagsstämma 2012
2011-11-17 - Kvartalsrapport 2011-Q3
2011-10-31 - Extra Bolagsstämma 2011
2011-08-18 - Kvartalsrapport 2011-Q2
2011-05-19 - Kvartalsrapport 2011-Q1
2011-02-25 - Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2021-03-23 20:39:48
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA,
CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL.

Lille/Oslo, 23 March 2021

Reference is made to the offer document dated 8 March 2021 (the "Offer
Document") for the recommended voluntary offer by Compagnie des Levures Lesaffre
(the "Offeror") to acquire all outstanding shares of NattoPharma ASA
("NattoPharma") against a consideration in cash of NOK 35 per share (the
"Offer").

Upon expiry of the acceptance period at 16:30 CET on 23 March 2021, and based on
a preliminary review, the Offeror has received acceptances under the Offer
which, together with shares already owned by the Offeror and options shares the
Offeror has agreed to acquire subject to completion of the Offer, in total
amount to 16,073,191 shares, representing in total 76.40% of issued and
outstanding shares in NattoPharma (on a fully diluted basis, excluding treasury
shares).

Based on the above, the closing conditions "Minimum Acceptance" and "Regulatory
Approval" are considered to be fulfilled.

Please note that the calculation of the number of shares tendered in the
voluntary Offer is preliminary and remains subject to potential adjustments
through a verification process currently being undertaken by the receiving agent
for the Offer. The final result of the Offer will be announced once confirmed by
the receiving agent. Such announcement is currently expected in the morning of
24 March 2021.

Rothschild is acting as financial adviser to the Offeror and Nordea Bank Abp,
filial i Norge, is acting as receiving agent. Advokatfirmaet Thommessen AS is
acting as the Norwegian legal adviser, and Linklaters is acting as the French
legal adviser, to the Offeror in connection with the Offer.

ABG Sundal Collier ASA is acting as financial adviser and Advokatfirmaet CLP DA
is acting as Norwegian legal adviser to NattoPharma.

For further information, please contact:

NattoPharma:
NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

Lesaffre:
Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr

About NattoPharma:
NattoPharma is a public limited liability company listed on Euronext Expand Oslo
and is headquartered in Oslo. NattoPharma is the world's leader in vitamin K2
research and development, and is the owner and exclusive distributer of MenaQ7®
Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending, and now the new MenaQ7® Full Spectrum, which
delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements.

About Lesaffre:
A key global player in fermentation for more than a century, Lesaffre, with a
2.2 billion euro turnover, and established on all continents, counts 10,700
employees and more than 85 nationalities. On the strength of this experience and
diversity, we work with customers, partners and researchers to find ever more
relevant answers to the needs of food, health, naturalness and respect for our
environment. Thus, every day, we explore and reveal the infinite potential of
microorganisms.

To nourish 10 billion people, in a healthy way, in 2050 by making the most of
our planet's resources is a major and unprecedented issue. We believe that
fermentation is one of the most promising answers to this challenge.

Important notice:
The Offer and the distribution of this announcement and other information in
connection with the Offer may be restricted by law in certain jurisdictions.
Lesaffre and the Offeror assume no responsibility in the event there is a
violation by any person of such restrictions. Persons into whose possession this
announcement or such other information should come are required to inform
themselves about and to observe any such restrictions.

THE OFFER WILL NOT BE MADE IN ANY JURISDICTION IN WHICH MAKING OF THE OFFER
WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH JURISDICITON. THIS ANNOUNCEMENT
DOES NOT IN ITSELF CONSTITUTE AND OFFER. THE OFFER WILL ONLY BE MADE ON THE
BASIS OF THE OFFER DOCUMENT AND CAN ONLY BE ACCEPTED PURSUANT TO THE TERMS OF
SUCH DOCUMENT.

The Offer is subject to disclosure and procedural requirements of the Kingdom of
Norway which are different from those in the United States. In addition, the
payment and settlement procedures with respect to the Offer will comply with the
relevant Norwegian rules, which differ from United States payment and settlement
procedures.

This information is subject to the disclosure requirements of NattoPharma
pursuant to section 5 -12 of the Norwegian Securities Trading Act.